Display options
Cite
Karchava M, Waldenström J, Parker M, et al. High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment. Hepatol Res. 2015;45(13):1292-8doi: 10.1111/hepr.12505.
Karchava, M., Waldenström, J., Parker, M., Hallack, R., Sharvadze, L., Gatserelia, L., Chkhartishvili, N., Dvali, N., Dzigua, L., Dolmazashvili, E., Norder, H., & Tsertsvadze, T. (2015). High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment. Hepatology research : the official journal of the Japan Society of Hepatology, 45(13), 1292-8. https://doi.org/10.1111/hepr.12505
Karchava, Marine, et al. "High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment." Hepatology research : the official journal of the Japan Society of Hepatology vol. 45,13 (2015): 1292-8. doi: https://doi.org/10.1111/hepr.12505
Karchava M, Waldenström J, Parker M, Hallack R, Sharvadze L, Gatserelia L, Chkhartishvili N, Dvali N, Dzigua L, Dolmazashvili E, Norder H, Tsertsvadze T. High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment. Hepatol Res. 2015 Dec;45(13):1292-8. doi: 10.1111/hepr.12505. Epub 2015 Mar 24. PMID: 25689487; PMCID: PMC4787595.
Copy Download .nbib Format: NLM
Share it on

Hepatol Res. 2015 Dec;45(13):1292-8. doi: 10.1111/hepr.12505. Epub 2015 Mar 24.

High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment.

Hepatology research : the official journal of the Japan Society of Hepatology

Marine Karchava, Jesper Waldenström, Monica Parker, Renee Hallack, Lali Sharvadze, Lana Gatserelia, Nikoloz Chkhartishvili, Natia Dvali, Lela Dzigua, Ekaterine Dolmazashvili, Helene Norder, Tengiz Tsertsvadze

Affiliations

  1. Infectious Diseases, AIDS and Clinical Immunology Research Center.
  2. Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
  3. David Axelrod Institute, Wadsworth Center, Albany, New York, USA.
  4. Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia.

PMID: 25689487 PMCID: PMC4787595 DOI: 10.1111/hepr.12505

Abstract

AIM: The first hepatitis C virus (HCV) recombinant, RF2k/1b, was initially described from Russia and has since then been identified from patients in Ireland, Estonia, Uzbekistan and Cyprus. Many of these patients originated from Georgia; however, there is no information on its prevalence in Georgia or its susceptibility to antiviral treatment.

METHODS: We retrospectively sequenced the non-structural region 5B (NS5B) of the HCV genome in samples from 72 Georgian patients, 36 of whom had been treated with pegylated interferon and ribavirin.

RESULTS: The HCV genotype was determined using the Versant HCV Genotype v2 kit. Based on this typing, 32 patients (44.4%) were infected with genotype 1, 21 (29.1%) genotype 2 and 19 (26.3%) genotype 3. Partial NS5B of these strains was sequenced and analyzed for type, with concordant genotype results for all type 1 and 3 strains. Discrepant results were observed for genotyped 2 strains, with 16 (76%) having NS5B of subtype 1b. On phylogenetic analysis, 15 NS5B sequences of these strains were found in a clade formed by recombinant RF2k/1b strains. The remaining discordant sequence was found within a clade formed by 1b strains.

CONCLUSION: Our findings show that the RF2k/1b recombinant strain is common among Georgian patients previously assumed to be infected with genotype 2. Because genotyping is mainly performed to decide treatment strategies, there is a need to determine the genotype by analysis of at least two genomic regions in strains from Georgian patients considered infected with genotype 2 based on standard HCV genotyping methods.

© 2015 The Japan Society of Hepatology.

Keywords: hepatitis C virus sequence; hybrid virus; interferon treatment; phylogenetic analysis

References

  1. Hepatol Res. 2008 May;38(5):457-64 - PubMed
  2. N Engl J Med. 1996 Jan 11;334(2):77-81 - PubMed
  3. Ann Intern Med. 2004 Mar 2;140(5):346-55 - PubMed
  4. J Med Virol. 2007 Apr;79(4):374-82 - PubMed
  5. Georgian Med News. 2008 Dec;(165):71-7 - PubMed
  6. J Viral Hepat. 2011 Feb;18(2):77-83 - PubMed
  7. Lancet. 2001 Sep 22;358(9286):958-65 - PubMed
  8. Lancet Infect Dis. 2013 May;13(5):401-8 - PubMed
  9. Hepatology. 2008 Jul;48(1):38-47 - PubMed
  10. J Clin Virol. 2010 Apr;47(4):382-6 - PubMed
  11. J Virol. 2007 Apr;81(8):4357-62 - PubMed
  12. Mol Biol Evol. 2013 Dec;30(12):2725-9 - PubMed
  13. N Engl J Med. 2001 Jul 5;345(1):41-52 - PubMed
  14. J Clin Microbiol. 2008 Jun;46(6):1901-6 - PubMed
  15. J Hepatol. 2014 Aug;61(2):373-95 - PubMed
  16. N Engl J Med. 2013 Aug 15;369(7):678-9 - PubMed
  17. J Infect Dis. 2013 Jul;208(1):17-31 - PubMed
  18. J Med Virol. 2006 Nov;78(11):1423-8 - PubMed
  19. Ann Intern Med. 2004 Mar 2;140(5):370-81 - PubMed
  20. Virol J. 2006 Nov 15;3:95 - PubMed
  21. Semin Liver Dis. 2004;24 Suppl 2:25-31 - PubMed
  22. J Virol. 2006 Aug;80(15):7569-77 - PubMed
  23. Euro Surveill. 2014 Oct 30;19(43):null - PubMed
  24. J Clin Microbiol. 2007 Apr;45(4):1140-5 - PubMed
  25. J Virol. 2012 Feb;86(4):2212-20 - PubMed
  26. N Engl J Med. 2002 Sep 26;347(13):975-82 - PubMed
  27. J Med Virol. 2010 Feb;82(2):232-8 - PubMed
  28. Hepatology. 2015 Feb;61(2):471-80 - PubMed
  29. J Virol. 2002 Apr;76(8):4034-43 - PubMed
  30. J Infect Dis. 2008 Nov 15;198(10 ):1448-56 - PubMed
  31. Adv Virol. 2011;2011:710438 - PubMed

Publication Types

Grant support